Contineum Therapeutics (CTNM) EBITDA Margin (2023)

Contineum Therapeutics (CTNM) recorded quarterly EBITDA Margin of 83.02% in Q2 2023.

Contineum Therapeutics (CTNM) EBITDA Margin (2023) Analysis & Trends

Contineum Therapeutics' EBITDA Margin history runs 1 years deep, the most recent figure standing at 83.02% for Q2 2023.

In Q2 2023, EBITDA Margin changed N/A year-over-year to 83.02%; the TTM figure through Jun 2024 stood at 63.02% (changed N/A YoY), while the FY2023 annual figure was 45.81%, changed N/A from the prior year.
EBITDA Margin was 83.02% for Q2 2023 at Contineum Therapeutics.
In the past five years, EBITDA Margin ranged from a high of 83.02% in Q2 2023 to a low of 83.02% in Q2 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-6.43%
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	38.10%
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Contineum Therapeutics	423.05 Mn	423.05 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2023	83.02%